RESEARCH REPORT Michael Kaufman A dose-adjusted regimen of etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (DA-EPOCH-R) obviated the need for radiotherapy in patients with primary mediastinal B-cell lymphoma in a single-group, phase II, prospective study. RESEARCH REPORT Anna Azvolinsky Researchers have identified a novel monoclonal antibody directly targeted against a receptor found in abundance on chronic lymphocytic leukemia (CLL) cells, but not normal B cells. The humanized antibody can directly kill CLL cells. RESEARCH REPORT Michael Kaufman Targeting the bone marrow–specific extracellular matrix osteopontin may be an effective strategy to increase the efficacy of chemotherapy in patients with acute lymphocytic leukemia, according to the authors of a recent study.
REVIEW ARTICLE Shadi Latta, et al; ONCOLOGY Vol. 27 No. 2 In this review, we critically analyze clinical trials that were specifically designed for the very elderly, and we discuss the challenges encountered by investigators who are conducting studies in this patient population. • When Can R-CHOP Not Be Used in an Elderly Patient? • DLBCL in the Elderly: Leaving Our Old Way(s) Behind?
Diffuse Large B-Cell Non-Hodgkin Lymphoma in the Very Elderly: Challenges and Solutions
Shadi Latta, MD
Peter H. Cygan, MD 1,
Walter Fried, MD 1,
Chadi Nabhan, MD, FACP 1 , February 15, 2013
In this review, we critically analyze clinical trials that were specifically designed for the very elderly, and we discuss the challenges encountered by investigators who are conducting studies in this patient population. We conclude by proposing an algorithm to help clinicians determine the optimal therapeutic strategy for treatment of DLBCL in very elderly patients.
• When Can R-CHOP Not Be Used in an Elderly Patient?
• The Case for Refining Our Clinical Trials
• DLBCL in the Elderly: Leaving Our Old Way(s) Behind?
Combined-Modality Therapy for Early-Stage Hodgkin Lymphoma: Maintaining High Cure Rates While Minimizing Risks
Chris R. Kelsey, MD
1, Anne W. Beaven, MD 2, Louis F. Diehl, MD 2, Leonard R. Prosnitz, MD 1 , December 17, 2012
In Hodgkin lymphoma, as with many other malignancies, a combined-modality approach has proven successful. This tactic capitalizes on the relative advantages of both modalities, yet minimizes risk by avoiding intense exposure to either. This article will summarize the data supporting this approach in early-stage Hodgkin lymphoma.
• The Important Role of Secondary Treatment in Hodgkin Lymphoma
• Treatment for Favorable Localized Hodgkin Lymphoma
Is Imatinib Still an Acceptable First-Line Treatment for CML in Chronic Phase?
John M. Goldman, DM, FRCP, FRCPath, FMedSci
David Marin, MD, FRCP 1 , October 12, 2012
Is it reasonable to start all new CML patients on treatment with imatinib alone and continue the drug indefinitely in those who fare well, or should one start treatment with one of the newer agents or possibly with imatinib in combination with another anti-CML agent in order to secure the best possible outcome for an individual patient?
• Front-Line TKI Therapy for Chronic-Phase CML: the Luxury of Choice
• Which TKI Should Be Recommended as Initial Treatment for CML in Chronic Phase?
Treatment of Adult Acute Lymphoblastic
Leukemia (ALL) With a Focus on Emerging
Investigational and Targeted Therapies
Michael S. Mathisen, PharmD
Elias Jabbour, MD 2,
Hagop M. Kantarjian, MD 2 , September 12, 2012
In this review, we will discuss the management of ALL in the adult population, in the context of the recently published guidelines from the NCCN. We will focus in particular on the strides being made in salvage and targeted approaches.
• Treatment of Adult ALL: More Questions Than Answers
• ALL in Adults: How Can We Do Better?
Unfavorable, Complex, and Monosomal Karyotypes: The Most Challenging Forms of Acute Myeloid Leukemia
Johnnie J. Orozco, MD, PhD
1,2, Frederick R. Appelbaum, MD 1,2 , August 3, 2012
Although the overall prognosis for patients with acute myeloid leukemia (AML) associated with unfavorable, complex, or monosomal karyotypes is poor, some patients can be cured.
• Acute Myeloid Leukemia: The Challenge of Unfavorable Cytogenetics
• Acute Myeloid Leukemia With Adverse Cytogenetic Risk
Improving the Therapeutic Ratio in Hodgkin Lymphoma Through the Use of Proton Therapy
Bradford S. Hoppe, MD, MPH
Stella Flampouri, PhD 1,
James Lynch, MD 2,
William Slayton, MD 3,
Robert Zaiden, MD 4,
Zuofeng Li, DSc 1,
Nancy P. Mendenhall, MD 1 , May 15, 2012
This review addresses the rationale and evidence for—and the challenges, cost implications, and future development of—proton therapy as an important part of the treatment strategy in Hodgkin lymphoma.
• Protons: Moving Therapy for Hodgkin Lymphoma in a Positive Direction
• Proton Radiotherapy: The Good, the Bad, and the Uncertain
Showing 1 - 10 of 26 results.
May 15, 2013
DLBCL of any stage remains a systemic disease with early hematogenous spread. Thus, arguments advocating the role of IFRT do not truly address disease...
April 3, 2013
Researchers have identified a novel monoclonal antibody directly targeted against a receptor found in abundance on chronic lymphocytic leukemia (CLL)...
February 15, 2013
In this review, we critically analyze clinical trials that were specifically designed for the very elderly, and we discuss the challenges encountered...
December 21, 2012
A genome-wide study, and analysis of genes in Reed-Sternberg cells, suggest molecular subtypes that should lead to better therapies and prognostic...
December 18, 2012
Richter's transformation, or Richter's syndrome, is an uncommon clinicopathological condition observed in about 5% to 10% of patients with chronic...
Showing 1 - 5 of 218 results.
Latest Treatment and Research for Chronic Myeloid Leukemia
Michael Deininger, MD, PhD
1 , December 24, 2012
In this interview we discuss the latest chronic myeloid leukemia treatment and research with Dr. Michael Deininger, chief of the division of hematology at the University of Utah School of Medicine.
Hematology Letters is a new blog for Cancer Network written by Mojtaba Akhtari, MD of the University of Nebraska Medical Center, Omaha, Nebraska.
Abdominal Mass Found in 53-Year-Old Patient
February 15, 2013
A 53-year-old woman presented with abominal pain. Physical examination and radiographic imaging shows the presence of an abdominal mass. Biopsy of the mass was performed. What is your diagnosis?
LEUKEMIA & LYMPHOMA MEDICATIONS
SEARCHMEDICA SEARCH RESULTS
Find peer-reviewed literature and websites for practicing medical professionals